to investigate the short-term efficacy and safety of drug-eluting bead transcatheter arterial chemoembolization (deb-tace) using callispheres® microspheres in the treatment of unresectable locally advanced breast cancer (labc).
deb-tace using csm was performed in 15 patients with labc after failure of medical treatment. the efficacy was evaluated based on the modified response evaluation criteria in solid tumors (mrecist). the postoperative adverse reactions and complications were analyzed. the changes of white blood cell (wbc) count, creatine kinase isoenzyme-mb (ck-mb), b-type natriuretic peptide (bnp), and carbohydrate antigen15-3 (ca15-3) before and after treatment were compared by using wilcoxon signed-rank test.
对15例治疗失败的labc患者行callispheres®载药微球栓塞治疗(deb-tace)。根据改良实体肿瘤反应评估标准(mrecist)评估疗效，分析介入术后不良反应及并发症。采用wilcoxon signed-rank检验比较治疗前后白细胞计数(wbc)、肌酸激酶同工酶-mb (ck-mb)、b型利钠肽(bnp)、肿瘤抗原15-3 (ca15-3)的变化。
the surgeries were successful in all patients. the subjects were followed up for 2–60 months (median: 10 months). according to the mrecist, no patient achieved complete remission (cr) 1, 3, and 5 months after surgery, and partial response (pr) was achieved in 9, 11, and 11 cases; also, there were 6, 4, and 2 stable disease (sd) cases, and 0, 0, and 2 progressive disease (pd) cases. the postoperative wbc count, ck-mb level, and bnp level were not significantly different from those before surgery, whereas the ca15-3 level significantly decreased. the main postoperative adverse reactions were pain, fever, and gastrointestinal reactions. no severe adverse reactions were observed.
所有患者均顺利完成介入手术。患者随访2-60个月(中位数：10个月)。根据mrecist标准，术后1、3、5个月，没有患者达到完全缓解(cr)；9、11、11例患者达到部分缓解(pr)；疾病稳定(sd) 患者6例，4例，2例；疾病进展(pd) 患者0例，0例，2例。术后wbc计数、ck-mb、bnp水平与术前无明显差异，而ca15-3水平较术前明显下降。术后主要不良反应表现为疼痛、发热及胃肠道反应，未见严重不良反应发生。
deb-tace with callispheres® microspheres is a safe and feasible treatment for labc. however, more multi-center studies with larger sample sizes are still warranted.